TransMedics Group (NASDAQ:TMDX) Hits New 12-Month Low – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price hit a new 52-week low on Wednesday . The company traded as low as $55.00 and last traded at $56.73, with a volume of 2322802 shares. The stock had previously closed at $57.20.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird cut their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Down 0.8 %

The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of 60.35 and a beta of 2.12. The firm has a 50 day simple moving average of $70.87 and a 200-day simple moving average of $117.01. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.12) EPS. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of the stock. Sachetta LLC bought a new position in TransMedics Group in the 4th quarter worth approximately $40,000. Cornerstone Wealth Management LLC bought a new stake in shares of TransMedics Group during the fourth quarter worth $231,000. Janney Montgomery Scott LLC acquired a new position in shares of TransMedics Group during the fourth quarter valued at $239,000. HB Wealth Management LLC boosted its holdings in TransMedics Group by 49.2% in the fourth quarter. HB Wealth Management LLC now owns 8,149 shares of the company’s stock valued at $508,000 after acquiring an additional 2,689 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after acquiring an additional 322 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.